PEAK6’s Ginkgo Bioworks DNA Stock Holding History

PEAK6’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-107,163	Closed	-$896K	–	2842
2026 Q1	$657K	Sell	107,163 -55,674	-34%	-$463K	﹤0.01%	1869
2025 Q4	$1.35M	Buy	+162,837	New	+$1.75M	﹤0.01%	1628

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

PEAK6's DNA Position: Q2 2026 in Review

PEAK6 sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 107,163 shares — an estimated $896K sold.

PEAK6 first reported a position in DNA in Q4 2025 and held it in 2 quarters. The position peaked at $1.35M in Q4 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

PEAK6 reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
PEAK6 sold 107,163 Ginkgo Bioworks shares in Q2 2026, an estimated $896K.
PEAK6 first reported a position in Ginkgo Bioworks in Q4 2025 and held it in 2 quarters.
PEAK6's Ginkgo Bioworks position peaked at $1.35M in Q4 2025.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.